Used as an intermediate in the synthesis of folate-targeted pharmaceuticals, particularly in the development of antifolate agents for cancer therapy. It enables the conjugation of cytotoxic drugs to targeting moieties that bind to folate receptors overexpressed on certain tumor cells. This compound facilitates the formation of stable amide bonds through its active ester group, enhancing drug delivery specificity. Also employed in the preparation of antibody-drug conjugates (ADCs) where selective tumor cell targeting is required. Its structure supports linker construction in prodrug strategies, improving pharmacokinetics and reducing off-target effects.